Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cansino (Shanghai) Biological Research Co. Ltd. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This structure reflects a highly targeted prosecution effort within the biological research sector. The presence of 1 distinct art unit indicates that the company's current active filings are concentrated within a single specialized group at the USPTO.
The busiest examiner for the firm is SHOMER, ISAAC, who is handling 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution process is highly centralized. This single examiner, SHOMER, ISAAC, is responsible for the 1 pending office action that makes up the company's entire active portfolio. Because SHOMER, ISAAC is the sole examiner for the portfolio, the success of the current active matters depends on navigating the specific requirements of this individual. This 1 distinct examiner represents the entire point of contact for the firm's immediate prosecution needs.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576244 | IONIZABLE LIPID COMPOUND FOR NUCLEIC ACID DELIVERY AND LNP COMPOSITION THEREOF | SHOMER, ISAAC | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576244 | IONIZABLE LIPID COMPOUND FOR NUCLEIC ACID DELIVERY AND LNP COMPOSITION THEREOF | SHOMER, ISAAC | 9d |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576244 | IONIZABLE LIPID COMPOUND FOR NUCLEIC ACID DELIVERY AND LNP COMPOSITION THEREOF | SHOMER, ISAAC | 1612 | §102§103 | Final Rejection | 9d | Pending | Jan 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial